Materials Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Materials Select Sector SPDR Fund trades at $52.76, while Zimmer Biomet Holdings Inc trades at $96.44 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Materials Select Sector SPDR Fund pays none, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| XLB | ZBH | |
|---|---|---|
52-Week High | $53.62 | $107.71 |
52-Week Low | $42.23 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
XLB (Materials Select Sector SPDR ETF) trades at $52.68, down 0.94% on the day, while maintaining a bullish technical outlook with strong moving average support. The materials sector benefits from infrastructure spending and AI-related demand, though recent price action suggests some consolidation after the sector rebound. Technical indicators show mixed signals with overbought short-term RSI but strong trend momentum.
The ETF offers diversified exposure to materials companies with cyclical recovery potential, though valuation metrics appear limited after recent gains. Key risks include economic sensitivity and commodity price volatility, while positive earnings momentum and institutional interest provide support for long-term investors.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →